Ibudilast is a small molecule being developed by biopharmaceutical company MediciNova for the potential treatment of MS. The company, based in La Jolla, California, is currently calling the oral formulation MN-166.
In multiple sclerosis (MS), an errant immune response causes progressive brain and spinal cord demyelination, leading to cell death and tissue atrophy. The thalamus, a region of the brain responsible for processing sensory and motor information, is often affected in patients with MS.
Atrophy of the thalamus has been associated with several clinical outcomes of MS, including cognitive impairment, fatigue, pain, and mobility disorders. Because of this, thalamic atrophy is regarded as a highly important marker of MS disease progression.
Ibudilast is a small molecule being developed by biopharmaceutical company MediciNova for the potential treatment of MS. The company, based in La Jolla, California, is currently calling the oral formulation MN-166.
Ibudilast is a potential first-in-class glial attenuator designed to suppress the production of pro-inflammatory cytokines interleukin-1, interleukin-6, and tumor necrosis factor-alpha. In addition, it inhibits toll-like receptor 4 and macrophage migration inhibitory factor, both of which are elevated in the cerebrospinal fluid of individuals with MS and play a role in central nervous system inflammation.
The SPRINT-MS phase 2b study evaluated the effects of ibudilast in 255 participants with primary progressive MS (PPMS) and secondary progressive MS (SPMS). The study found a 48% decrease in brain atrophy in patients taking ibudilast versus those who received placebo and significant neuroprotective effects in the retina.
Kunio Nakamura, Ph.D., and his colleagues at the Cleveland Clinic in Cleveland, Ohio, analyzed data from the SPRINT-MS trial to determine whether treatment with ibudilast conferred similar neuroprotection in the thalamus among trial participants.
The new analysis results, published in the Multiple Sclerosis Journal earlier this month, showed that ibudilast exerted neuroprotection on intact tissue in the thalamus but did not significantly prevent thalamic atrophy over two years.
According to the researchers, the data suggests that “thalamic atrophy is more closely associated with global inflammatory activity than local tissue integrity”.
Ibudilast has been approved in Japan since 1989 to treat bronchial asthma and certain stroke complications. MediciNova is also investigating its use in other conditions, including amyotrophic lateral sclerosis and methamphetamine dependence. The company plans to launch a phase 3 trial to evaluate ibudilast’s effect on the rates of confirmed disability progression in patients with non-active SPMS.
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More
Ozanimod Shows Sustained Efficacy in Long-term Study for Multiple Sclerosis Treatment
March 11th 2024Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.
Read More